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Risk stratification in myeloma requires an accurate assessment of the presence of a range of molecular abnormalities
including the differing IGH translocations and the recurrent copy number abnormalities that can impact clinical behavior.
Currently, interphase fluorescence in situ hybridization is used to detect these abnormalities. High failure rates, slow turn-
around, cost, and labor intensiveness make it difficult and expensive to use in routine clinical practice. Multiplex ligation-
dependent probe amplification (MLPA), a molecular approach based on a multiplex polymerase chain reaction method,
offers an alternative for the assessment of copy number changes present in the myeloma genome. Here, we provide evi-
dence showing that MLPA is a powerful tool for the efficient detection of copy number abnormalities and when combined
with expression assays, MLPA can detect all of the prognostically relevant molecular events which characterize presenting
myeloma. This approach opens the way for a molecular diagnostic strategy that is efficient, high throughput, and cost
effective. VC 2014 The Authors. Genes, Chromosomes & Cancer Published by Wiley Periodicals, Inc.
INTRODUCTION
Multiple myeloma is a clonal disorder of plasma
cells (PCs) which accumulate in the bone marrow
resulting in cytopenias, bone resorption, renal
impairment, and the production of a monoclonal
protein (Kyle and Rajkumar, 2008). Myeloma is
both a clinically and biologically heterogeneous
disease, where key recurrent genetic lesions affect
outcome. These lesions are present in virtually all
cases and include balanced translocations involv-
ing the IGH locus on chromosome band 14q32
(30–40% of patients) and copy number abnormal-
ities affecting whole chromosomes, such as odd
numbered chromosomes in hyperdiploidy (50% of
patients) or specific regions on chromosome arms
1p32 (10%), 1q21 (30%), 12p (8%), 13q (35–40%),
16q (10%), or 17p (10%) (Walker et al., 2010, Boyd
et al., 2012).
Traditionally, conventional cytogenetics is used
to subtype the disease and detects most lesions
described above, but the difficulty in obtaining
metaphase spreads hampers the clinical utility of
this approach. In addition, karyotyping and G-
banding lack sensitivity, are not easily applied to
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the study of tumors with low proliferation indices,
such as myeloma, and yield results in only 35% of
all patients in clinical trial samples. In contrast to
metaphase cytogenetics, interphase fluorescence
in situ hybridization (iFISH) performed on
CD138-selected tumor cells offers a more viable
approach, giving conclusive results for t(4;14),
del(17p), and del(1p32)/gain(1q21), when enough
cells are available and in up to 70% of trial patients
(Myeloma IX trial, unpublished data). Neverthe-
less, this method is labor intensive and, as each
lesion is assessed independently, the full panel of
tests required to provide prognostically relevant
information is both expensive and labor intensive.
There is, therefore, a need for a novel diagnostic
tool able to detect the prognostically relevant
abnormalities in myeloma which is both high
throughput and applicable in a clinical setting.
Molecular approaches performed on DNA and
RNA from CD138-selected PCs would fulfill these
criteria and could be particularly useful in the
clinic. Detecting chromosomal translocations by
the overexpression of partner oncogenes using
quantitative reverse transcription polymerase
chain reaction (qRT-PCR) has been described
previously, but for prognostic purposes the copy
number variables also need to be assessed (Kaiser
et al., 2013). However, in the routine clinical set-
ting there is currently no alternative to iFISH for
the detection of copy number abnormalities.
Whole genome DNA analysis using comparative
genomic hybridization was a significant technical
development in molecular cytogenetics (Kallio-
niemi et al., 1992). A parallel technology utilizing
single nucleotide polymorphism (SNP) arrays has
been used to detect copy number changes and loss
of heterozygosity (Mullighan et al., 2007). Cost
and turnaround time renders array-based assays
difficult in a diagnostic setting. Recently, multi-
plex ligation-dependent probe amplification
(MLPA) was developed as a fast and robust alter-
native method to analyze copy number changes in
a wide set of loci. It is based on a multiplex PCR
method and is able to detect relative copy number
changes affecting small regions (55–80 nucleo-
tides) and single nucleotide aberrations in up to 46
genomic DNA regions per multiplex reaction
(Schouten et al., 2002; Alpar et al., 2013). Specific
panels have been recently developed for several
disease entities such as inherited conditions and
hematological malignancies including myeloma
(Alpar et al., 2013). To date, MLPA has only been
compared to iFISH outside clinical trials (Alpar
et al., 2013). In this work, our aim was to evaluate
a myeloma-specific commercially available set of
MLPA probes against the use of either SNP arrays
or iFISH for the detection of copy number abnor-
malities. The ultimate aim of this work is to deter-
mine the performance of an all molecular
diagnostic approach, comprising MLPA for copy
number abnormality and qRT-PCR for transloca-
tion assessment.
MATERIALS AND METHODS
The Myeloma IX Study
The MRC Myeloma IX trial recruited 1,970
newly diagnosed patients. The trial design and
results have been reported previously (Morgan
et al., 2012). In brief, the trial included two treat-
ment pathways: the intensive treatment pathway
for younger and fitter patients and the nonintensive
pathway for older and less fit patients. The inten-
sive pathway comprised high dose melphalan and
autologous transplantation after induction with
cyclophosphamide, thalidomide, and dexametha-
sone (CTD) or cyclophosphamide, vincristine, dox-
orubicin, and dexamethasone. The nonintensive
pathway consisted of a randomization to either atte-
nuated CTD (CTDa) or melphalan and predniso-
lone. All patients were subsequently randomized to
thalidomide maintenance or no thalidomide main-
tenance. The trial was approved by the MRC Leu-
kaemia Data Monitoring and Ethics committee
(MREC 02/8/95, ISRCTN68454111).
Patient Samples
Bone marrow aspirates from newly diagnosed
patients with multiple myeloma, entered into the
UK MRC Myeloma IX study, were obtained after
informed consent. PCs were selected using CD138
microbeads and magnet-assisted cell sorting (Milte-
nyi Biotec, Bergisch Gladbach, Germany) as
described previously and PC purity was confirmed
to be >90% in all cases by cytospin. RNA and
DNA were extracted using commercially available
kits (RNA/DNA mini kit or Allprep kit; QIAGEN)
according to manufacturers’ instructions.
iFISH Analysis
Interphase FISH analysis was performed on
CD138-selected PCs using the micro-iFISH tech-
nique and probes that have previously been docu-
mented (Boyd et al., 2012). Briefly, probes to
detect translocations (t(4;14), t(6;14), t(11;14),
t(14;16), t(14;20)), copy number abnormalities
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(del(1p32.3), gain(1q21), del(17p)), and hyperdi-
ploidy (gain of at least two of chromosomes 5, 9,
and 15) were used to identify those abnormalities
using the consensus cut-offs defined by the iFISH
myeloma workshop (Ross et al., 2012).
Array Analysis
GeneChip Mapping 500K Array set (Affymetrix)
were performed as previously described. Twenty
additional samples in this study had also been ana-
lyzed using SNP6. For mapping array data, the
SNP inferred copy number were obtained using
GTYPE and dChip, as previously described. Data
have previously been deposited as GEO accession
number GSE21349. Homozygous deletions were
identified as having an inferred copy number less
than 0.7, hemizygous deletions between or equal
to 0.7–1.4, and gains> 2.4 for 500K arrays. Simi-
larly, for SNP6, homozygous deletions were
defined as a ratio less than 1.6, hemizygous dele-
tions as a ratio between or equal to 1.6 and 2.4,
and gains if the ratio was greater than 2.4.
MLPA Analysis
Fifty nanograms of DNA were subjected to
SALSA MLPA P425-B1 multiple myeloma probe-
mix developed by MRC-Holland (Amsterdam, The
Netherlands). The probemix contained 46 probes
for the following regions (genes): 1p32.3-p32.2
(FAF1, CDKN2C, PPAP2B, and DAB1), 1p31.3-
p31.2 (LEPR and RPE65), 1p21.3-p21.1 (DPYD and
COL11A), 1p12 (FAM46C), 1q21.3 (CKS1B), 1q23.3
(NUF2 and PBX1), 5q31.3 (PCDHA1, PCDHAC1,
PCDHB2, PCDHB10, SCL25A2, and PCDHGA11),
9p24 (JAK2), 9q34 (COL5A1) 12p13.31 (CHD4,
VAMP1, CD27, and NCAPD2), 13q14 (RB1, DLEU1,
and DIS3), 13q22.1 (DIS3), 14q32.32 (TRAF3),
15q12 (GABRB3), 15q26 (IGF1R), 16q12 (CYLD),
16q23 (WWOX), and 17p13 (TP53). In addition, this
probemix contained 11 reference probes, locating in
genomic regions that are relatively stable in multi-
ple myeloma, allowing reliable normalization and
data analysis of the results. MLPA reactions, includ-
ing internal quality controls and negative controls,
were performed according to the manufacturer’s
instructions. The PCR products were analyzed
using an ABI 3730 DNA analyser (Life Technolo-
gies, Paisley, UK) and Coffalyser.net software
(MRC Holland, Amsterdam, The Netherlands).
Copy number at each locus was estimated as
described previously (Schwab et al., 2010). In sum-
mary, values above 1.2, between or equal to 1.2 and
0.75, between or equal 0.75 and 0.25, and below
0.25 were considered as gain, normal, hemizygous
loss, and homozygous loss, respectively. Values
above 1.6 were consistent with amplification (more
than three copies).
Statistical Analysis
Performance of the classification function of
iFISH and MLPA were measured against SNP
arrays using the R Caret package. Survival curves
were plotted using the Kaplan–Meier method.
Differences between curves were tested for statis-
tical significance using the log-rank test, with
P< 0.05 taken as the level of significance.
RESULTS
Frequency of Abnormalities Detected by iFISH,
SNP Arrays, and MLPA
Eighty six patients were assessable for a compari-
son between iFISH, MLPA, and 500K arrays. Copy
number abnormalities (including del(1p32),
gain(1q21), del(13q), del(16q), del(17p), and hyper-
diploidy) were identified in 60 patients using 500K
arrays (70%), 76 patients (88%) using iFISH, and
67 patients (78%) using MLPA. The frequency of
each individual abnormality is given in Table 1.
There was good concordance of results between
different assays with the iFISH and MLPA giving
more consistent results than with mapping arrays,
which generally underestimates the frequency of
abnormalities. The most discordant results we
TABLE 1. Frequency of Main Genetic Lesion Determined by Mapping Arrays, iFISH, and MLPA (n5 86)
500K arrays % (n 5) iFISH % (n 5) MLPA % (n 5)
Del(1p32) (CDKN2C-FAF1) 11% (10) 17% (15) 15% (13)
Gain(1q21) (CKS1B) 27% (23) 34% (29) 31% (27)
Del(13q) (RB1) 34% (29) 49% (42) 48% (41)
Del(16q23) (WWOX) 14% (12) 27% (23) 22% (19)
Del(17p) (TP53) 3.5% (3) 7% (6) 4.6% (4)
Hyperdiploidy (gain of 5–9-15) 27% (23) 46% (40) 49% (42)
Overall 70% (60) 88% (76) 78% (67)
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obtained were seen with del(17p) (3.5% for map-
ping array, 7% for iFISH, and 4.6% for MLPA).
However, this reflects a difference of one patient
given the low frequency of del(17p) in the patient
cohort. Adverse prognostic lesions such as
gain(1q21), del(1p32), and del(17p) were found in
38% of patients by MLPA, 32% by 500K arrays,
and 43% by iFISH. Multiple adverse aberrations
(del(1p32), gain(1q21), and del(17p)) were present
in several patients, as previously described, result-
ing in cosegregation in 12, 9, and 14% of patients
by MLPA, 500K arrays, and iFISH, respectively.
Comparison of MLPA and SNP Arrays
Eighty six samples were assessable for MLPA,
500K arrays, and iFISH. When MLPA and iFISH
were compared to 500K arrays, MLPA was associ-
ated with better sensitivity and specificity than
iFISH for the different regions analyzed (Table 2).
The sensitivity and specificity of MLPA in detect-
ing del(17p) deletions were 100 and 99% versus
100 and 97% for iFISH, respectively. Given the
small number of del(17p) in this dataset, an addi-
tional comparison was made between MLPA and a
series of samples enriched for PC leukemia for
which SNP6 data were available (n5 29). Twelve
samples had del(17p) in this dataset and the sensi-
tivity of MLPA was 94% and the specificity 100%
when compared to SNP6 arrays (Table 3). For
CDKN2C, located at 1p32, losses were detected
with a sensitivity and specificity of 100 and 97%
versus 100 and 93% for iFISH. In the expanded
analysis using the SNP6 dataset, the sensitivity of
MLPA for CDKN2C was 83% and the specificity
100%. The sensitivity of MLPA to detect WWOX
deletions was 100% both for MLPA and iFISH but
the specificity of MLPA was greater (92% vs. 84%).
The loss of CYLD is not assessed by common
iFISH probes but MLPA was able to detect them
with good sensitivity (100%) and specificity (93%)
when compared to 500K array. The sensitivity of
detecting del(13q) by MLPA was lower than iFISH
(97% vs. 100%) but MLPA yielded better specific-
ity (77% vs. 71%). To facilitate comparisons, we
defined hyperdiploidy in the three methods as
being the gain of at least two chromosomes among
chromosome 5, 9, and 15. The sensitivity of detect-
ing hyperdiploidy was 100%, but MLPA lacked
specificity (80%) like iFISH (75%) suggesting both
methods currently overestimate hyperdiploidy. In
addition, compared to iFISH, MLPA offers addi-
tional information regarding other regions of inter-
est in myeloma (FAF1, CYLD, TRAF3, and
FAM46C) with a very good concordance of results
compared to SNP arrays (Table 2).
Comparison of MLPA and iFISH
One hundred and seventy-one patients derived
from the Myeloma IX study had both iFISH and
TABLE 2. Sensitivities and Specificities versus iFISH and CGH Arrays: MLPA and iFISH Compared to 500K SNP Arrays for the
Detection of Copy Number Changes (n5 86)
Gene (locus)
MLPA iFISH
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
FAF1 (1p32) 92 92
CDKN2C (1p32) 100 97 100 93
FAM46C (1p12) 100 96
TP53 (17p) 100 99 100 97
CYLD (16q12) 100 93
WWOX (16q23) 100 91 100 84
CKS1B (1q21) 95 89 90 82
NUF2, RP11, and PBX1 (1q23) 80 91
Overall 1q gain 95 86 90 82
RB1 (13q14) 97 77 100 71
TRAF3 (14q32) 100 95
Hyperdiploidy (gain of 5–9-15) 100 80 93 75
TABLE 3. Sensitivities and Specificities versus iFISH and CGH
Arrays: MLPA Compared to SNP6 Arrays for the Detection






FAF1 (1p32) 90 100
CDKN2C (1p32) 83 100
FAM46C (1p12) 100 80
TP53 (17p) 94 100
CYLD (16q12) 100 96
WWOX (16q23) 100 96
CKS1B (1q21) 94 92
NUF2, RP11, and PBX1 (1q23) 100 84
Hyperdiploidy (gain of 5–9-15) 100 96
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MLPA data available. When compared to iFISH,
specificities were good (Table 4). The specificity
of MLPA to detect TP53 (del(17p)) deletions and
FAF1-CDNK2C (1p32) deletions were 99% but the
sensitivities were lower (76 and 80%, respec-
tively). Similar results were seen with 1q21
(CKS1B), 13q (RB1), 16q (WWOX), and hyperdi-
ploidy confirming the results observed when com-
pared to the 500K arrays and suggesting MLPA
could underestimate the number of lesions.
As MLPA can deliver a semiquantitative assess-
ment, one can determine the relative number of
copies of CKS1B and, therefore, differentiate
between gain and amplification of 1q21. By apply-
ing k-mean clustering to the average of two probes
for CKS1B in 264 patients, we were able to
TABLE 4. Sensitivities and Specificities versus iFISH and CGH Arrays: MLPA Compared to iFISH for the Detection of Copy
Number Changes (n5 171)
Gene (locus) Sensitivity (%) Specificity (%) Frequency by iFISH (%) Frequency by MLPA (%)
TP53 (17p) 76 99 15 12
CDKN2C (1p32) 80 99 17 15
CKS1B (1q21) 79 94 44 39
Hyperdiploidy (gain of 5–9-15) 79 94 57 40
RB1 (13q14) 91 95 55 50
WWOX (16q23) 72 98 27 21
Figure 1. MLPA for identification of gains and amplifications of
CKS1B was associated with a negative impact on survival in this small
dataset. Panel A: Distribution of CKS1B ratios. By applying k-mean clus-
tering to 264 MLPA CKS1B raw values, we were able to identify normal
patients with two copies of CKS1B (ratio range from 0.83 to 1.19, cen-
ter5 1.02), patients with a gain or three copies of CKS1B (range1.2–
1.59, center 1.36), and a small subset of patients with CKS1B amplifica-
tion (range 1.63–2.53, center 1.86). Panel B and C: Survival analysis.
Survival data were available for the 176 Myeloma IX samples and sug-
gests that amplification is associated with a worse outcome in terms of
both PFS (Panel B) and OS (Panel C).
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identify patients with two copies of CKS1B (ratio
range from 0.83 to 1.19, center5 1.02), patients
with a gain (three copies) of CKS1B (range 1.2–
1.59, center 1.36), and a small subset of patients
with CKS1B amplification (range 1.63–2.53, center
1.86). The specificity in detecting amplification
using a ratio >1.6, when compared to patients
with more than three copies of CKS1B by iFISH,
was good (96%). The sensitivity was nevertheless
low (56%). Of note, all the false positives were in
fact gained but one bore a subclonal amplification
by iFISH (39% of cells). We were also able to
show that amplification of 1q21 was present in
8.5% of patients at diagnosis and associated with a
negative impact on survival in this small dataset,
Figure 1.
Results of an All Molecular Approach for the
Detection of High Risk Myeloma
We went on to implement this diagnostic strat-
egy in combination with our previously described
expression-based assay for the detection of recur-
rent translocations involving the IGH locus (Kaiser
et al., 2013). In a series of 154 patients from the
Myeloma IX trial, which were analyzed by qRT-
PCR for translocations and MLPA for copy num-
ber abnormality, 53% of patients had at least one
adverse lesion defined as the presence of a t(4;14),
t(14;16), t(14;20), del(1p32), gain(1q21), and
del(17p). Patients with an adverse prognostic
lesion did significantly worse than those with none
with a median Profression-Free Survival (PFS) of
14.9 (95% CI 13.2–19.9) versus 23.0 (95% CI 18.5–
30.1) months and a median Overall Survival (OS)
of 35.8 (95% CI 38.3–62.1) versus 47.6 (95% CI
28.8–43.7) months (Figure 2). These data suggest
that an all molecular approach can be used to
define outcome.
DISCUSSION
Over the last 15 years, it has become clear that
specific genetic lesions have an importance on the
tumor biology of myeloma. Increasing evidence
suggests that myeloma is not a single disease but a
collection of diseases with distinct clinical behav-
iors. Understanding this heterogeneity will enable
us to perform precision medicine where clinical
decisions are based on molecular subtypes of
disease. Identifying these groups and designing
clinical trials for them will refine our current man-
agement strategies, avoiding overtreating or under-
treating specific subgroups (ClinicalTrials.gov,
n.d.). The first step toward precision medicine is
applying a risk stratification approach based on
prognostically important lesions. Translocations
were first identified as being prognostic with more
recent studies emphasizing the role of copy number
changes such as gain(1q21), del(1p32), and del(17p)
(Avet-Loiseau et al., 2011; Boyd et al., 2012; Avet-
Loiseau et al., 2012, 2013; Hebraud et al., 2014). To
increase the sensitivity and specificity of such
approaches for the demonstration of clinical out-
comes (Boyd et al., 2012), it is important to detect
all the prognostically relevant lesions present in a
myeloma cell, an aim which is technically difficult
with iFISH.
Although RNA-based classifications have been
developed to identify translocations (Bergsagel
and Kuehl, 2005; Kaiser et al., 2013), there is cur-
rently no equivalent molecular approach to detect
Figure 2. Survival analysis of high-risk patients as determined by
MLPA and PCR-based translocation assay. Panel A: PFS, Panel B: OS.
Survival analysis of patients with one or more adverse prognostic
lesion (such as t(4:14), t(14;16), t(14;20), del(17p), del(1p32), or
gain(1q21)) versus those with none as determined by MLPA and PCR-
based translocation assay. Patients with adverse prognostic lesions did
significantly worse than those with none (median PFS and OS were,
respectively, 14.9 (95% CI 13.2–19.9) and 35.8 (95% CI 28.3–62.1)
months in the high-risk group and 22.1 (95% CI 18.5–30.1) and 47.6
(95% CI 28.8–43.7) months in the nonhigh-risk group).
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copy number changes in a routine clinical setting.
MLPA is a cost effective and robust method that
can analyze up to 50 independent genetic loci in a
single reaction. MLPA has been used in multiple
diagnostic settings in both benign and malignant
conditions, such as neurogenetic disorders, lym-
phoma, and acute leukemia. (Coll-Mulet et al.,
2008; Schwab et al., 2010; Donahue et al., 2011;
Alpar et al., 2013). We show that MLPA is applica-
ble to sorted CD138 myeloma cells where it is a
highly effective tool to accurately access a wide
panel of copy number abnormalities present
at diagnosis when compared to SNP arrays.
Discrepancy between iFISH and MLPA probably
relate to point mutations, cryptic lesions, or sub-
clones, as previously shown in chronic lymphocytic
leukemia (Verone`se et al., 2013). The comparison
of MLPA to mapping arrays demonstrates the
power of this method, as for each lesion the sensi-
tivity and specificity is better than when using
iFISH.
Importantly, MLPA can be used to determine
the number of copies of each region, which is of
clinical relevance as amplification of CKS1B is
associated with disease progression (Sawyer et al.,
2014). We show for the first time that amplification
of CKS1B is present in approximately 8% of
patients at diagnosis and has a negative impact on
survival. No high amplification samples were seen
in our dataset (maximum five inferred copies). As
far as the prognostic impact of the other lesions is
concerned the exact prognostic relevance of each
individual lesion remains to be determined, but
our analysis suggests that MLPA may be used in
combination with expression assays to determine a
molecular risk stratification in myeloma, thus pro-
viding a rapid and robust alternative to iFISH.
MLPA also offers additional information in
comparison to iFISH. By tiling other regions of
interest, MLPA broadens the spectrum of analysis.
MLPA covers 15 regions: some covered by stand-
ard FISH panels (TP53, CDKN2C, etc.) and some
other ones that bear a more mechanistic relevance
such as CYLD and TRAF3. The latter are associ-
ated with NF-jB activation, a feature that corre-
lates with an aggressive disease phenotype and
may constitute an interesting new target in
myeloma (Annunziata et al., 2007).
As far as cost is concerned, although they are
likely to vary between centers and the number of
samples processed, the estimated cost of this
MLPA panel is roughly 60–70 e which is much
less than the estimated cost of iFISH (six probes
750 e) and SNP arrays (350–500 e).
Thus, MLPA offers a powerful alternative to
iFISH which in its current format is able to deter-
mine copy number abnormalities at 15 independ-
ent loci. We show that MLPA can accurately
determine recurrent copy number abnormalities
and that it can be readily applied in a diagnostic
laboratory at low cost.
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